1. Home
  2. INCR vs XLO Comparison

INCR vs XLO Comparison

Compare INCR & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intercure Ltd.

INCR

Intercure Ltd.

HOLD

Current Price

$0.88

Market Cap

47.4M

Sector

Health Care

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$7.99

Market Cap

49.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INCR
XLO
Founded
1994
2016
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.4M
49.8M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
INCR
XLO
Price
$0.88
$7.99
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$28.00
AVG Volume (30 Days)
30.5K
28.5K
Earning Date
05-01-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,766,000.00
Revenue This Year
$69.54
N/A
Revenue Next Year
$41.75
$168.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
589.88
52 Week Low
$0.68
$0.46
52 Week High
$1.77
$9.25

Technical Indicators

Market Signals
Indicator
INCR
XLO
Relative Strength Index (RSI) 45.10 52.36
Support Level $0.84 $7.47
Resistance Level $0.93 $8.80
Average True Range (ATR) 0.07 0.37
MACD -0.02 -0.05
Stochastic Oscillator 6.24 51.64

Price Performance

Historical Comparison
INCR
XLO

About INCR Intercure Ltd.

Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: